Pyxis Oncology is transforming the lives of patients with cancer by advancing our differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppression. We believe that antibody-drug conjugates (ADCs) and immunotherapies have the potential to address difficult-to-treat cancers and improve patient outcomes.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $174M
Founded date: 2019
Founders name: ZE-QI (ZQ) XU
Founders Related Locations: Haiti, Centre, Hinche; United States, Illinois, Chicago; United States, Massachusetts, Boston
Investors 5
| Date | Name | Website |
| - | Agent Capi... | agentcapit... |
| - | RA Capital... | racap.com |
| - | Skydeck Ca... | skydeckllc... |
| - | Perceptive... | perceptive... |
| - | HBM Partne... | hbmpartner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 31.03.2021 | Series B | $152M | - |
| 18.07.2019 | Series A | $22M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | ZE-QI (ZQ) | XU | Chairman a... | linkedin.c... | - | - |
Mentions in press and media 17
| Date | Title | Description |
| 12.11.2024 | Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024 | - Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30 p.m. ET - Preliminary data from the Phas... |
| 13.03.2024 | Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA | - |
| 07.03.2024 | Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024 | - |
| 05.03.2024 | Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting | - |
| 21.03.2023 | This VC built a lab to make building biotech startups easier | When you think of life sciences and biotech hubs in the U.S., where do you travel to in your mind? Boston? The Bay Area? Texas? Portal Innovations, a biotech VC firm based in Chicago, is trying to broaden everyone’s horizons and give opport... |
| 29.03.2022 | Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology | - Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106), a fully human anti-Siglec-15 monoclonal antibody - Biosion earns a $10 million upfront license fee; additional milestone pa... |
| 31.03.2021 | Pyxis Oncology closes $152M Series B | Pyxis Oncology, a developer of therapeutics for difficult-to-treat cancers, has raised a $152 million Series B co-led by Arix Bioscience and RTW Investments. Perceptive Advisors, RA Capital Management, Pfizer Ventures and a host of others p... |
| 30.03.2021 | After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B | It’s been a nice month for Pyxis Oncology: After penning a major licensing deal with Pfizer, the startup now has $152 million extra in the bank to help it push on with its expanded pipeline. A few weeks back, Pfizer out-licensed two of its ... |
| 30.03.2021 | Pyxis Oncology Raises $152M Series B Round | CAMBRIDGE, MA, Pyxis Oncology today announced the closing of a $152 million Series B financing. >> Click here for more funding data on Pyxis Oncology >> To export Pyxis Oncology funding data to PDF and Excel, click here T... |
| 30.03.2021 | After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B | It’s been a nice month for Pyxis Oncology: After penning a major licensing deal with Pfizer, the startup now has $152 million extra in the bank to help it push on with its expanded pipeline. This also built on the ADC licensed from LegoChem... |
Show more